pyrotinib tablet + Montmorillonite Power + Loperamide
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Recurrent / Metastatic Breast Cancer
Conditions
HER2-positive Recurrent / Metastatic Breast Cancer
Trial Timeline
Mar 8, 2022 → Aug 2, 2022
NCT ID
NCT05252546About pyrotinib tablet + Montmorillonite Power + Loperamide
pyrotinib tablet + Montmorillonite Power + Loperamide is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for HER2-positive Recurrent / Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05252546. Target conditions include HER2-positive Recurrent / Metastatic Breast Cancer.
What happened to similar drugs?
0 of 15 similar drugs in HER2-positive Recurrent / Metastatic Breast Cancer were approved
Approved (0) Terminated (0) Active (15)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05252546 | Phase 1 | Completed |
Competing Products
20 competing products in HER2-positive Recurrent / Metastatic Breast Cancer